Figure 1.

Routine PET imaging in neuro-oncology. PET/CT techniques for neuropathologic imaging are dominated by radiopharmaceuticals focussing on altered glucose metabolism (desoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG)), amino acid metabolism (L-[¹¹C]-methyl-methionine ([¹¹C]MET), O-2-[¹⁸F]fluoroethyl-L-tyrosine ([¹⁸F]FET), 3,4-dihydroxy-6-[¹⁸F]fluoro-L-phenylalanine ([¹⁸F]F-DOPA)), proliferation (3'-deoxy-3'-[¹⁸F]fluoro-thymidine [¹⁸F]FLT)), tumoral hypoxia sensing ([¹⁸F]fluoro-misonidazole ([¹⁸F]FMISO), [¹⁸F]fluoro-azomycin arabinoside ([¹⁸F]FAZA)), and lipid metabolism ([¹¹C]choline ([¹¹C]Cho), [¹⁸F]fluoroethyl-choline ([¹⁸F]FCho)). Abbreviations: High affinity choline transporter (CHT), choline kinase (CHK), equilibrative nucleoside transporter (ENT), 2'-fluoro-2'-deoxy glucose-6-phosphate (FDG-6-P), glucose transporter (GLUT), hexokinase (HK), nitroreductase (NTR), partial pressure of oxygen (pO₂), Na+-independent plasma membrane amino acid transport (System L), thymidine kinase (TK). Adapted with permission from ¹⁸, copyright 2017 Codon Publications.